Who shouldn't take hormone therapy? Contraindications, gray areas, and your non-hormonal options.

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published November 13, 2026 · Updated November 13, 2026

Hormone therapy can be an important option for bothersome hot flashes and night sweats. It is not right for everyone.

That distinction is getting more attention as interest in hormone therapy (HT) grows. At The Menopause Society's 2026 Annual Meeting, held October 20–24 in San Diego, Arina Chesnokova, MD, MPH, of the University of Pennsylvania, presented an electronic health record study of outpatient family medicine, internal medicine, and general obstetrics and gynecology encounters among women aged 45 to 60 years in the University of Pennsylvania Health System. As reported by Patient Care, after adjustment for annual encounter volume, prescribing of hormone therapy or combined contraception to women with a contraindication rose from 3.2 per 10,000 encounters in 2022 to 14.8 in 2025 and 23.1 through April 2026 (incidence rate ratio per year, 1.64; 95% CI, 1.54–1.75).

A few limits matter as much as the rates. This was a meeting presentation (Abstract P-19), not a peer-reviewed journal article; we are working from Patient Care's report, not the poster itself. "The raw numbers are still really small," Chesnokova said, noting that breast cancer and blood clots accounted for most of the contraindications. The increase comes amid growing attention to hormone therapy, including FDA labeling changes, although the study did not examine causes. The figures count hormone therapy or combined contraception, not hormone therapy alone, and the 23.1 rate is through April 2026, so that year is incomplete.

This post asks a practical question those findings raise: according to current FDA labeling, in what situations should menopausal hormone therapy not be used? Which situations are not listed as contraindications but still need an individualized talk with a clinician? And if hormones are not appropriate, or not preferred, what do current guidelines say about nonhormonal options? It complements our recent article on whether there is an age limit on hormone therapy. This article does not advise you to start, stop, or avoid any medicine; those decisions belong with you and a licensed clinician.

What a contraindication means—and what it does not

On a drug label, a contraindication is a situation in which the medicine should not be used. That is stricter than a risk factor, a family history, or an age or timing consideration that belongs in a shared decision. Being over 60, or more than 10 years from menopause, is not by itself a contraindication on the labels we reviewed; timing and age are covered in our recent post.

In November 2025, FDA asked manufacturers of menopausal hormone therapies to remove language about cardiovascular diseases, breast cancer, and probable dementia from the boxed warning. "Removed from the boxed warning" is not "no risks," and it is not a statement that contraindications went away. For systemic products, FDA asked that cardiovascular disease and breast cancer warnings remain in the labeling. See our boxed-warning explainer for what those changes did and didn't do.

What current FDA labels list as contraindications

FDA's public list of menopausal hormone therapies with updated prescribing information—content current as of October 30, 2026—names nine products. That list does not itself spell out contraindications. For this article, we read the February 2026 prescribing information for two of those products: Enjuvia (systemic estrogen alone) and Bijuva (systemic estrogen and progestogen). Their contraindication lists agree on the clinical conditions below. Other products, including vaginal estrogen and progestogen-alone capsules, can differ. Always check the label for the specific medicine, and talk with a clinician. Naming a product here does not mean Kindr Health prescribes it.

These products are contraindicated in women with any of the following:

• Undiagnosed abnormal genital bleeding (abnormal vaginal bleeding whose cause has not been found)
• Breast cancer, current or in the past
• Estrogen-dependent neoplasia (a tumor that depends on estrogen)
• Active deep vein thrombosis (DVT) or pulmonary embolism (PE), or a history of these conditions (blood clots in the legs or lungs)
• Active arterial thromboembolic disease, such as stroke or myocardial infarction (heart attack), or a history of these conditions
• Hepatic impairment or disease (liver impairment or liver disease)
• Known thrombophilic disorders, such as protein C, protein S, or antithrombin deficiency, or other known clotting disorders
• Known anaphylactic reaction, angioedema, or hypersensitivity to that specific product

Hormone therapy isn't right for everyone: depending on age, timing, health history and the type used, it can raise the risk of blood clots, stroke and breast cancer, and estrogen without a progestogen raises the risk of uterine cancer in people who have a uterus. People who have a uterus and use systemic estrogen typically still need a progestogen.

Gray areas: when the decision is individualized

Many situations are not listed as contraindications and still call for a careful, individualized discussion—not an automatic yes or no.

Timing and age are one example. FDA asked companies to add consideration of starting hormone therapy for moderate to severe hot flashes in women younger than 60 or less than 10 years since menopause. ACOG, in its October 15, 2026, news page on expanded menopause guidance, recommends that initiating hormone therapy be based on shared decision-making, considering symptoms; the benefits and risks of therapy based on age, medical history, and baseline risks of cardiovascular disease, breast cancer, and venous thromboembolism (blood clots); and individualized treatment goals and priorities. If selected, ACOG recommends initiating hormone therapy before age 60 or within 10 years of the start of spontaneous (natural) menopause, in people without contraindications. That is timing guidance for starting, not a contraindication, and not a mandatory stop rule at 60 or 65.

Preference is another. ACOG's news page recognizes that some people may have contraindications to hormone therapy or would prefer not to use it, and it reviews evidence-based nonhormonal options for that reason.

Warnings and precautions on the label are not the same as contraindications. On the February 2026 Enjuvia label, for example, clinicians are told to exercise caution in a woman with a history of cholestatic jaundice associated with past estrogen use or pregnancy. The same label asks clinicians to consider whether benefits outweigh risks in several other conditions, including preexisting high triglycerides (which may be associated with pancreatitis), conditions that predispose to fluid retention such as cardiac or renal impairment, residual endometriosis after hysterectomy, and conditions estrogen therapy may exacerbate, including asthma, diabetes mellitus, epilepsy, migraine, and systemic lupus erythematosus. It also reports a higher risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens. These are reasons to talk with a clinician who knows your history—not a complete list, and not a personal recommendation. Your product's label may differ.

If hormones are not appropriate: the ACP treatment ladder

If you cannot take hormone therapy, or you do not tolerate it, you still have options. In October 2026, the American College of Physicians (ACP) published a clinical guideline in Annals of Internal Medicine on pharmacologic treatments for menopausal vasomotor symptoms (hot flashes and night sweats). We are working from the official PubMed abstract; the full article is not open access.

For people seeking treatment of vasomotor symptoms, ACP's abstract lays out three rungs:

• First-line (strong recommendation, high-certainty evidence): estrogen combined with a progestogen in people who have a uterus, or estrogen alone in people who do not.
• Second-line (conditional recommendation), in people who have contraindications to or do not tolerate first-line treatment: a serotonin-norepinephrine reuptake inhibitor (SNRI), either desvenlafaxine or venlafaxine (moderate-certainty evidence).
• Third-line (conditional recommendation), in people who have contraindications to or do not tolerate first-line or second-line treatment: a selective serotonin reuptake inhibitor (SSRI), either escitalopram or paroxetine (low-certainty evidence); gabapentin (low-certainty evidence); or a neurokinin receptor antagonist, either elinzanetant or fezolinetant (moderate-certainty evidence).

Those third-line medicines are alternatives at the same rung, not a required sequence from SSRIs to gabapentin to the neurokinin drugs. ACP also says that when selecting a treatment, clinicians should use an informed decision-making approach and discuss benefits, harms, contraindications, comorbid conditions, values and preferences, financial burden, and access to and availability of treatments.

ACP's October 5, 2026, newsroom summary matches that order.

This ladder is guidance for clinicians treating vasomotor symptoms, not a personal prescription. Not every medicine on it is FDA-approved specifically for menopausal hot flashes; fezolinetant (Veozah) and elinzanetant (Lynkuet) are, and a low-dose form of paroxetine is as well, as we discussed in more detail. Veozah has a boxed warning for serious liver injury (hepatotoxicity), and your clinician will order liver blood tests before you start, monthly for the first 3 months, and again at 6 and 9 months; Lynkuet's label includes a warning about seizures, it is contraindicated in pregnancy, it can cause sleepiness and other nervous-system effects, and liver blood tests are required before starting and at 3 months. Low-dose paroxetine has its own boxed warning (suicidal thoughts and behaviors, as with other SSRIs). Naming a medicine does not mean Kindr Health prescribes it, or that it is right for you. Nonhormonal options have their own risks, side effects, and, for some, monitoring requirements. They are not interchangeable.

ACOG's October 2026 news page also reviews evidence-based nonhormonal pharmacologic options, including neurokinin receptor antagonists such as fezolinetant and elinzanetant, and SSRIs and SNRIs, which can help manage vasomotor symptoms and depression in people who have one or both. It discusses nonpharmacologic approaches (including cognitive behavioral therapy, mindfulness-based interventions, exercise, clinical hypnosis, and acupuncture), generally recommended in combination with hormonal or other medicines. ACOG also underscores that evidence does not support the safety or efficacy of phytoestrogens or herbal supplements for vasomotor or other menopausal symptoms; those products are not regulated by the FDA and have not been tested for safety, efficacy, or purity.

What to share at intake so a clinician can screen safely

A clinician cannot screen for contraindications without your history. Before a visit, it helps to be ready to share:

1. Cancers and bleeding: any history of breast cancer or an estrogen-dependent tumor, and any unexplained vaginal bleeding.
2. Clots and cardiovascular events: any deep-vein thrombosis, pulmonary embolism, stroke, or heart attack—now or in the past—and any known clotting disorder (including protein C, protein S, or antithrombin deficiency).
3. Liver and other conditions: liver disease or liver impairment; a history of jaundice related to estrogen or pregnancy; and other conditions your clinician should weigh, such as those in the gray-area section above.
4. Allergies, medicines, and preferences: allergic reactions to hormone medicines; everything you currently take; your symptoms; and whether you prefer to consider nonhormonal options.

This is not a complete medical-history form, and it is not a substitute for a clinician's evaluation. If something is uncertain—a past diagnosis, a family history, a medicine you used years ago—say so.

Where Kindr fits

At Kindr Health, menopause and midlife care is clinician-led. Conversations about hormone therapy are individualized: your symptoms, your health history—including contraindications and other risk factors—and your goals. Kindr Health is a telehealth platform that connects patients with licensed clinicians, who can talk through whether hormone therapy is appropriate for you, and what nonhormonal options may be available if it is not or is not preferred. Hormone therapy is not an automatic yes, and a contraindication is not something to work around. Kindr Care patient intake is open now.

This article is for educational purposes only and is not medical advice. Talk with your clinician before starting, stopping, or changing any medication. See our medical disclaimer.

Medically reviewed by Kindr Health Clinical Team
Last updated: November 13, 2026